Therapeutics / News / PR Newswire / Syndication / biotechnology / Health Care / Hospitals / Medical / Pharmaceuticals / Surveys / Polls & Research

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

Posted on: Sep 16, 2020   |   Posted by: Biotech Mag

Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery - SAN DIEGO, Sept. 16, 2020...




Other Posts from Biotech Mag